EQUITY RESEARCH MEMO
Cinclus Pharma
Generated 5/10/2026
Executive Summary
Conviction (model self-assessment)65/100
Cinclus Pharma is a Swedish clinical-stage pharmaceutical company dedicated to developing novel small molecule therapies for gastric acid-related diseases. Founded in 2015 and headquartered in Stockholm, the company's lead candidate, linaprazan glurate, targets severe gastroesophageal reflux disease (GERD) and Helicobacter pylori infection. Unlike existing proton pump inhibitors, linaprazan glurate is designed to provide superior acid suppression and improved symptom control, addressing an unmet need in patients with refractory GERD or inadequate response to current therapies. The company's pipeline is focused on this single asset, positioning it for a concentrated development effort.
Upcoming Catalysts (preview)
- Q4 2026Phase 1 top-line data readout for linaprazan glurate70% success
- Q2 2027Initiation of Phase 2 clinical trial for severe GERD65% success
- H2 2027Potential strategic partnership or licensing deal40% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)